We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Breath Test Identifies Heart Failure in Patients

By LabMedica International staff writers
Posted on 11 Apr 2013
Acute decompensated heart failure (ADHF) is the most common indication for hospital admission, particularly in the elderly where using conventional clinical methods is unreliable.

The identification of those with impending decompensation frequently leaves insufficient lag time for therapeutic interventions, but by analyzing single puff of exhaled air from patients, it is possible to quickly determine whether they have heart failure.

Scientists at the Cleveland Clinic (Cleveland, OH, USA), collaborating with others, conducted a prospective, single-center cohort study to assess the feasibility of exhaled breath analysis to identify patients admitted for ADHF. More...
Of the 61 patients involved in the study, 25 had been hospitalized with heart failure as a primary diagnosis, 16 were healthy controls, and another 36 people were added to validate the positive research findings.

All breath analyses were performed within two hours of collection using selected ion flow tube mass spectrometry instrument (VOICE200 SIFT-MS, Syft Technologies; Christchurch, New Zealand). The investigators were able to correctly diagnose heart failure in all the patients who had been hospitalized with the disease. The breath test not only identified all the patients with heart failure, but also clearly distinguished them from cardiac cases without heart failure. The exhaled breath of patients with heart failure had considerably higher levels of organic compounds acetone and pentane, compared to those without heart failure.

Raed Dweik, MD, a pulmonologist and lead-investigator, in the Respiratory Institute at Cleveland Clinic, said, "While additional examination is needed to determine the true potential of breath analysis for heart failure identification in our patients, we're very encouraged by these results. The ability to identify patients with heart failure using a breath test has the potential for broad application due to its noninvasive nature and ease of application.” The authors concluded that future studies in exhaled breath metabolomics are needed to accelerate progress in the field of cardiovascular medicine. The study was published on April 2, 2013, in the Journal of the American College of Cardiology.

Related Links:

Cleveland Clinic
Syft Technologies




Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Capillary Blood Collection Tube
IMPROMINI M3
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.